Regulus Therapeutics (RGLS) Stock Chart & Stock Price History $8.16 0.00 (0.00%) As of 06/25/2025 Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Regulus Therapeutics Stock Price Performance The Regulus Therapeutics (RGLS) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 391.57%, with a year-to-date return of 416.46%. In the past month, the stock has increased 0.74%, reflecting recent market activity. As of the latest close, Regulus Therapeutics traded at $8.16 with a market cap of $564.92 million and volume of 0 shares. Five years ago, the stock traded at a split-adjusted price of $7.10, representing a 14.93% increase over that period. At the time, it had a market cap of $14.34 million and a volume of 1.39 million shares. Receive RGLS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day PerformanceN/A1 Month Performance+0.74%3 Month Performance+384.27%Year-To-Date Performance+416.46%1 Year Performance+391.57%5 Year Performance+14.93% RGLS Stock Chart for Saturday, July, 5, 2025 RGLS Chart by TradingView Regulus Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/25/2025$8.16$8.04-1.53%$8.18$8.079.34 million shs$556.30 million06/24/2025$8.14$8.16+0.25%$8.18$8.079.32 million shs$564.92 million06/23/2025$7.88$8.14+3.30%$8.17$8.055.00 million shs$563.53 million06/20/2025$8.21$7.88-4.02%$8.24$7.7517.02 million shs$545.56 million06/19/2025$8.21$8.21$8.29$8.171.37 million shs$568.38 million06/18/2025$8.20$8.21+0.12%$8.29$8.171.37 million shs$568.38 million06/17/2025$8.22$8.20-0.24%$8.24$8.161.16 million shs$567.72 million06/16/2025$8.11$8.22+1.36%$8.28$8.071.16 million shs$569.10 million06/13/2025$8.08$8.11+0.37%$8.12$8.02970,988 shs$561.49 million06/12/2025$8.15$8.08-0.86%$8.15$8.061.27 million shs$559.41 million Get the Latest News and Ratings for RGLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 06/11/2025$8.30$8.15-1.81%$8.32$8.15714,583 shs$564.26 million06/10/2025$8.30$8.30$8.31$8.22727,464 shs$574.64 million06/09/2025$8.22$8.30+0.97%$8.35$8.221.48 million shs$574.64 million06/06/2025$8.10$8.22+1.48%$8.28$8.072.78 million shs$569.10 million06/05/2025$7.95$8.10+1.89%$8.13$7.982.36 million shs$560.80 million06/04/2025$7.97$7.95-0.25%$7.99$7.94686,079 shs$550.41 million Related Companies Ligand Pharmaceuticals Stock Price Chart BioCryst Pharmaceuticals Stock Price Chart Amicus Therapeutics Stock Price Chart Celldex Therapeutics Stock Price Chart Innoviva Stock Price Chart Dynavax Technologies Stock Price Chart MannKind Stock Price Chart OPKO Health Stock Price Chart Novavax Stock Price Chart Geron Stock Price Chart Receive RGLS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:RGLS) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
